Artemisinin-based monotherapies for malaria are explicitly discouraged to avoid the problem of developing resistance to the newer treatment.
[4] In a recent study about solid cancers, Martin Nowak, Bert Vogelstein, and colleagues showed that in most clinical cases, combination therapies are needed to avoid the evolution of resistance to targeted drugs.
[1] Various systems biology methods must be used to discover combination therapies to overcome drug resistance in select cancer types.
[5][6] Recent precision medicine approaches have focused on targeting multiple biomarkers found in individual tumors by using combinations of drugs.
[7] The National Cancer Institute has recently highlighted combination therapy as a top research priority in oncology.